Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Valve Repair or Replacement Offers Similar Outcomes for Severe Heart Valve Disease

Published: Monday, December 09, 2013
Last Updated: Monday, December 09, 2013
Bookmark and Share
NIH clinical study provides first rigorous comparison of these two surgical options for leaky mitral valve.

Repair or replace? Consumers often ask this question when considering faulty cars, appliances, or other equipment.

A new clinical study has now addressed this question for a serious medical decision: how to treat ischemic mitral regurgitation (IMR), a condition in which blood backflows into the heart because the mitral valve becomes leaky after a heart attack.

The study compared the two surgical options -re-tightening the leaky mitral valve or replacing it with a prosthetic -and found no significant differences in patient outcomes after a year.

This was the first randomized clinical trial comparing these two approaches for IMR. It was carried out by the Cardiothoracic Surgical Trials Network (CTSN), a consortium supported by the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institute of Health, along with the Canadian Institutes of Health Research (CIHR).

"This study addressed an important question for a clinically vulnerable patient group," said Michael Lauer, M.D., director of NHLBI's Division of Cardiovascular Sciences. "People who have ischemic mitral regurgitation not only have bad valves, they have bad hearts. It's critical we know the right procedure for these patients."

Although the CTSN study did not find differences in health outcomes, the results still provide implications for surgeons, noted CTSN investigator Michael Acker, M.D., of the University of Pennsylvania Perelman School of Medicine, Philadelphia, who will present the results at the American Heart Association (AHA) Scientific Sessions in Dallas. "The medical community has recently gravitated towards valve repair as a preferred treatment option for IMR. The evidence this study presents does not suggest mitral valve repair is superior."

The results of the Severe Mitral Regurgitation (SMR) trial will be published in the New England Journal of Medicine to coincide with the AHA presentation.

IMR affects over 1 million people in the United States and can pose serious health consequences. The leaky valve, by forcing the heart to pump some blood backward, makes the heart work harder, which can eventually lead to heart failure, stroke, or sudden cardiac arrest.

In severe cases, repairing or replacing the mitral valve is necessary. Both approaches offer benefits and risks, but as of yet no study has rigorously evaluated these approaches to see if the trade-offs result in significant differences in patient outcomes.

The SMR study enrolled 251 patients who had been diagnosed with severe IMR. These patients were then evenly randomized to receive surgical repair (a valve tightening procedure called an annuloplasty) or a prosthetic replacement mitral valve.

The participants were then monitored at one, six and 12 months after their procedure. The investigators examined how well the surgery worked by measuring the shrinkage of the heart's left ventricle, which enlarges with chronic valve leakage. The study also measured various health outcomes as well as patient-assessed quality of life.

After a year of follow-up, there were almost no differences in ventricle shrinkage or health outcomes between the two treatments. The only significant change was a higher rate of recurrent regurgitation in the repair group (32.6 percent of repair patients versus 2.3 percent of replacement patients).

"The increased level of recurrent regurgitation falls in line with valve replacement offering more durable long-term protection," noted Annetine Gelijns, Ph.D., CTSN investigator at the Icahn School of Medicine at Mount Sinai in New York City, and corresponding author of the study. "However, such regurgitation did not lead to any noticeable increases of health problems among patients in the repair group."

Gelijns said the SMR study will continue to monitor the participants until they reach 24 months post-procedure, to see if long-term differences emerge, which may help identify patient groups better suited for repair or replacement.

The study was carried out at 22 participating CTSN centers across the United States and Canada. The International Center for Health Outcomes and Innovation Research, Icahn School of Medicine at Mount Sinai hospital in New York City, served as the coordinating center.

"The Canadian Institutes of Health Research are proud to support the CTSN and the Canadian researchers involved in this study," said Dr. Jean Rouleau, scientific director of the CIHR Institute of Circulatory and Respiratory Health. "This cross-border collaborative research is helping both our countries to answer questions that directly impact treatment decisions our health care providers will make."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Saturday, July 25, 2015
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
Tuesday, July 21, 2015
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Tuesday, July 21, 2015
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Tuesday, July 21, 2015
NIH-funded Vaccine for West Nile Virus Enters Human Clinical Trials
Enrollment is expected to be completed by December 2015.
Tuesday, July 07, 2015
In Blinding Eye Disease, Trash-Collecting Cells Go Awry, Accelerate Damage
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Friday, July 03, 2015
Boys More Likely to Have Antipsychotics Prescribed, Regardless of Age
NIH-funded study is the first look at antipsychotic prescriptions patterns in the U.S.
Thursday, July 02, 2015
New Medication for Alcohol Use Disorder
NIH begins clinical trial investigating a potential treatment for alcohol use disorder.
Friday, June 26, 2015
NIH Begins Clinical Trial of New Medication for Alcohol Use Disorder
Clinical trial will evaluate the safety and effectiveness of gabapentin enacarbil in treating alcohol use disorder.
Friday, June 26, 2015
Study of Ebola Survivors Opens in Liberia
Trial to examine long-term health effects of Ebola virus disease.
Friday, June 19, 2015
NIH Names Walter J. Koroshetz, M.D. Director of the NINDS
Dr. Collins recognized Dr. Koroshetz’ role in the creation of the StrokeNet.
Saturday, June 13, 2015
NCI-MATCH Trial will Link Targeted Cancer Drugs to Gene Abnormalities
Precision medicine trial will open to patient enrollment in July.
Tuesday, June 09, 2015
Linking Targeted Cancer Drugs to Gene Abnormalities
Investigators at the NIH have announced a series of clinical trials that will study drugs or drug combinations that target specific genetic mutations.
Wednesday, June 03, 2015
Starting Antiretroviral Treatment Early Improves Outcomes for HIV-infected Individuals
NIH-funded trial results likely will impact global treatment guidelines.
Thursday, May 28, 2015
Two Treatments Yield Similar Results for Children After Cardiac Arrest
NIH-funded research finds therapeutic hypothermia no more effective than normal temperature control.
Friday, May 08, 2015
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!